For research use only. Not for therapeutic Use.
Anabaseine is a non-selective nicotinic agonist. Anabaseine stimulates all AChRs, preferentially stimulates skeletal muscle and brain α7 subtypes[1][2]. Anabaseine is also a weak partial agonist at α4β2 nAChRs[3].
Anabaseine is a full agonist at α7 AChR in the central nervous system (CNS) and a full agonist at α1β1ɛδ and α1β1γδ (Torpedo) in the peripheral nervous system[1].
Anabaseine acts as neuromuscular agonist on the frog rectus abdominis muscle (EC50: 0.25-0.74 μM)[1].
Anabaseine (3.6 μmol/kg; subcutaneous injection) elevates ACh levels[1].
| Catalog Number | R001632 |
| CAS Number | 3471-05-4 |
| Synonyms | 3-(2,3,4,5-tetrahydropyridin-6-yl)pyridine |
| Molecular Formula | C10H12N2 |
| Purity | ≥95% |
| InChI | InChI=1S/C10H12N2/c1-2-7-12-10(5-1)9-4-3-6-11-8-9/h3-4,6,8H,1-2,5,7H2 |
| InChIKey | AUBPMADJYNSPOA-UHFFFAOYSA-N |
| SMILES | C1CCN=C(C1)C2=CN=CC=C2 |
| Reference | [1]. Kem W, et al. The Nemertine Toxin Anabaseine and Its Derivative DMXBA (GTS-21): Chemical and Pharmacological Properties. Mar Drugs. 2006;4(3):255-273. [2]. Summers KL et al. Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex. Jpn J Pharmacol. 1997 Jun;74(2):139-46. [3]. Andrud K, et al. Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist Anabaseine. Mar Drugs. 2019;17(11):614. Published 2019 Oct 29. |
